Trials / Sponsors / Compass Therapeutics
Compass Therapeutics
Industry · 5 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | A Phase 1 Study of the Safety and Tolerability of CTX-10726 Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer | Phase 1 | 2026-04-01 |
| Recruiting | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma | Phase 1 | 2024-03-19 |
| Active Not Recruiting | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer | Phase 2 / Phase 3 | 2023-01-09 |
| Completed | A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer | Phase 2 | 2022-12-08 |
| Completed | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer | Phase 1 | 2019-05-17 |